KR101945207B1 - Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method - Google Patents
Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method Download PDFInfo
- Publication number
- KR101945207B1 KR101945207B1 KR1020170122412A KR20170122412A KR101945207B1 KR 101945207 B1 KR101945207 B1 KR 101945207B1 KR 1020170122412 A KR1020170122412 A KR 1020170122412A KR 20170122412 A KR20170122412 A KR 20170122412A KR 101945207 B1 KR101945207 B1 KR 101945207B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- lactic acid
- bacteria
- composition
- complex natural
- Prior art date
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 15
- 230000002708 enhancing effect Effects 0.000 title description 24
- 238000004519 manufacturing process Methods 0.000 title description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 241000894006 Bacteria Species 0.000 claims abstract description 72
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 38
- 239000004310 lactic acid Substances 0.000 claims abstract description 38
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 22
- 235000008397 ginger Nutrition 0.000 claims abstract description 22
- 235000013339 cereals Nutrition 0.000 claims abstract description 21
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 16
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 16
- 235000021014 blueberries Nutrition 0.000 claims abstract description 16
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 14
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 14
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 240000007594 Oryza sativa Species 0.000 claims description 25
- 235000007164 Oryza sativa Nutrition 0.000 claims description 25
- 235000009566 rice Nutrition 0.000 claims description 25
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 241000186660 Lactobacillus Species 0.000 claims description 16
- 229940039696 lactobacillus Drugs 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 13
- 244000068988 Glycine max Species 0.000 claims description 10
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 244000075850 Avena orientalis Species 0.000 claims description 8
- 235000007319 Avena orientalis Nutrition 0.000 claims description 8
- 244000199866 Lactobacillus casei Species 0.000 claims description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 8
- 229940017800 lactobacillus casei Drugs 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 235000021329 brown rice Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 3
- 241000186866 Lactobacillus thermophilus Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims 1
- 230000036737 immune function Effects 0.000 abstract description 18
- 210000000936 intestine Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 241000196324 Embryophyta Species 0.000 abstract description 11
- 241000234314 Zingiber Species 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000013325 dietary fiber Nutrition 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 235000007558 Avena sp Nutrition 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 229960002666 1-octacosanol Drugs 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 201000000628 Gas Gangrene Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000077233 Vaccinium uliginosum Species 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000066764 Ailanthus triphysa Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000579185 Bucerotidae Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001470651 Clostridium perfringens ATCC 13124 Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000025053 Escherichia coli DSM 30083 = JCM 1649 = ATCC 11775 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940111205 diastase Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052892 hornblende Inorganic materials 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- -1 orozanol Chemical compound 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A23Y2220/00—
-
- A23Y2300/29—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은, 장내 환경 개선 및 면역기능 향상 효과가 우수한 천연 식물을 추출하여 제조된 추출물에 유산균을 접종하여 발효시켜 조성물을 제조함으로써, 장내 부패균의 억제효과 및 유산균의 면역기능을 활성에 도움을 줄 수 있는 장내 환경 개선 및 면역기능 증강용 조성물의 제조방법 및 이에 의해 제조된 장내 환경 개선 및 면역기능 증강용 조성물에 관한 것이다.The present invention relates to a method for producing a composition by inoculating a lactic acid bacterium into an extract prepared by extracting a natural plant having excellent intestinal environment improvement and immune function improving effect, And to a composition for enhancing intestinal environment and enhancing immune function produced by the method.
현대인의 육류 위주의 식생활, 인스턴트 및 가공식품위주의 식습관, 자극성 있는 식품의 지나친 섭취, 바쁜 생활환경으로 성급해진 음식물 섭취 패턴의 변화 등 바람직하지 못한 식생활과 건전하지 못한 생활습관 그리고 나이가 들어감에 따라서 유익한 균들보다 유해한 균들이 우세하게 되어 장내 세균의 균형이 깨어져 장의 건강에 많은 악영향을 미치게 되어 소화불량, 변비, 대장암을 유발시킬 수 있다.Due to the undesirable dietary habits and unhealthy lifestyles of modern people, such as meat-based diet, instant and processed food-oriented eating habits, excessive consumption of irritating foods, Harmful bacteria are predominant over beneficial bacteria, and the balance of intestinal bacteria is broken, and adverse effects on the intestinal health are adversely affected, which can lead to indigestion, constipation and colorectal cancer.
따라서, 이러한 질병의 예방 및 개선을 위하여 운동요법 또는 더불어 건강 기능성 식품의 섭취 등 다양한 방안이 연구되고 있다. Therefore, in order to prevent and improve such diseases, various methods such as exercise therapy or ingestion of health functional food have been studied.
그 중에서도 장내에 서식하는 세균의 증식 및 활성화를 통해 장내 환경을 개선하기 위하여 다양한 건강 기능성 식품들에 대한 연구가 활발히 진행되고 있다.Among them, various health functional foods have been actively studied in order to improve intestinal environment through the proliferation and activation of germs in the intestines.
인체의 장 내부에는 유산균과 같이 건강에 유익한 균들과 그 외 건강에 유익하지 못한 유해한 균들, 크게 두 가지 집단의 균들이 서로 균형을 이루며 살아가고 있다. Inside the intestines of the human body, two kinds of bacteria are living in balance among harmful bacteria that are not beneficial for health, such as lactic acid bacteria and other health-beneficial bacteria.
인체의 장 내부에 충분한 유산균이 존재하게 되면 유산(젓산) 등의 산을 생성하여 장의 연동 운동을 자극하고, 장내 pH를 저하시켜 유해한 물질을 생성하는 유해균들의 증식을 억제하여 장 내부의 환경을 건강하게 유지시킬 수 있다. When there are enough lactic acid bacteria in the intestines of the human body, it will produce acid such as lactic acid to stimulate the peristaltic movement of the intestines and reduce the intestinal pH to suppress the proliferation of harmful bacteria producing harmful substances, .
일반적으로 유산균(lactic acid bacteria, lactobacillus)은 글루코오스 등 당류를 분해하여 젖산을 생성하는 세균으로 젖산균이라고도 불리며, 젖산발효에 의해 생성되는 젖산에 의해서 병원균과 유해세균의 생육이 저지되는 성질이 있어 유제품·김치류·양조식품 등의 식품제조에 이용하고 있다. 또한, 유산균은 포유류의 장내에 서식하여 잡균에 의한 이상발효를 방지하여 정장제(整腸劑)로도 이용되고 있다. 상기 유산균은 그람양성균으로, 통성혐기성 또는 혐기성을 성질을 지니며, 락토바실러스 속과 스트렙토코쿠스 속에 여러 종류가 알려져 있다. 한편, 대부분의 유산균은 혐기성이며 산에 약한 특성으로 인해 유산균을 식품으로 이용할 경우 장까지 도달하기 어렵다는 문제가 있었다.In general, lactic acid bacteria (lactobacillus) is a bacterium that produces lactic acid by decomposing saccharides such as glucose. It is also called lactic acid bacteria, and lactic acid produced by lactic acid fermentation inhibits the growth of pathogenic bacteria and harmful bacteria. It is used for food production such as kimchi, brewed food. In addition, lactic acid bacteria live in the intestines of mammals to prevent abnormal fermentation by germs and are also used as enteric agents. The above-mentioned lactic acid bacteria are gram-positive bacteria, and have various properties such as lactic acid, anaerobic or anaerobic, and Lactobacillus and Streptococcus. On the other hand, most of the lactic acid bacteria are anaerobic and have weak acidity, so that it is difficult to reach the lactic acid bacteria when they are used as food.
본 발명은, 천연 식물 중 장내 환경 개선 및 면역기능 향상 효과가 있는 유효 성분이 다량 함유된 연근, 블루베리, 생강 및 곡물을 추출, 발효하여 조성물을 제조함으로써, 장내 부패균의 억제효과 및 유산균의 면역기능을 활성에 도움을 줄 수 있는 장내 환경 개선 및 면역기능 증강용 조성물의 제조방법 및 이에 의해 제조된 장내 환경 개선 및 면역기능 증강용 조성물을 제시하고자 한다.The present invention relates to a method for producing a composition by extracting and fermenting rootstocks, blueberries, ginger and grains containing a large amount of active ingredient having an effect of improving intestinal environment and immune function in natural plants, The present invention provides a composition for enhancing the intestinal environment and enhancing the immune function, which is capable of enhancing the function of the intestinal environment, and a composition for enhancing the intestinal environment and enhancing the immune function.
상술한 바와 같은 목적을 달성하기 위한 본 발명의 일 실시 형태는, 연근, 블루베리, 생강 및 곡물 중 하나 이상을 분쇄하여 분쇄물을 제조하는 분쇄 단계; 상기 분쇄물을 중탕기를 사용하여 유효 성분을 추출하여 복합 천연 추출물을 제조하는 추출 단계; 상기 복합 천연 추출물을 가열하여 농축하는 농축 단계; 상기 농축 단계를 통해 수득된 복합 천연 농축액에 유산균을 접종하여 발효시키는 발효 단계; 및 상기 발효단계를 통해 수득된 복합 천연 발효물의 이물질을 제거하는 여과 단계; 를 포함하여 장내 환경 개선 및 면역기능 증강용 조성물을 제조하는 방법이다.According to an aspect of the present invention, there is provided a method for producing a pulverized product, comprising: grinding at least one of Lotus root, Blueberry, Ginger and Grain to produce a pulverized product; An extracting step of extracting the pulverized material from the active ingredient using a stewer to prepare a complex natural extract; Concentrating the complex natural extract by heating; A fermentation step of inoculating lactic acid bacteria into the complex natural concentrate obtained through the concentration step to ferment; And a filtration step of removing impurities of the complex natural fermentation product obtained through the fermentation step; Thereby improving the intestinal environment and improving the immune function.
상기 분쇄단계는, 연근, 블루베리, 생강 및 곡물을 1 : 0.1 ~ 10 : 0.1~ 10 : 0.1 ~ 10 중량비율로 혼합한 혼합물을 분쇄하여 분쇄물을 제조하는 것이 바람직하며, 이 때 제조된 분쇄물을 중탕기를 사용하여 40 ~ 80 ℃ 온도에서 300 ~ 500 bar 압력을 가하여 복합 천연 추출물을 제조할 수 있다.In the pulverizing step, it is preferable to produce a pulverized product by pulverizing a mixture obtained by mixing lotus root, blueberry, ginger and grain at a weight ratio of 1: 0.1 to 10: 0.1 to 10: 0.1 to 10, The complex natural extract can be prepared by adding water at a temperature of 40 to 80 ° C at a temperature of 300 to 500 bar using a stagnant water bath.
상기 농축 단계는, 복합 천연 추출물에 당 조성물을 추가한 다음, 가열하여 복합 천연 농축액을 제조할 수 있는데, 상기 당 조성물은, 포도당, 과당, 갈락토오스, 자당, 맥아당, 젖당 중 하나 이상을 포함하는 것을 사용할 수 있다.The concentration may be performed by adding the sugar composition to the complex natural extract and then heating to prepare a complex natural concentrate. The sugar composition may include one or more of glucose, fructose, galactose, sucrose, maltose and lactose Can be used.
바람직하게는 상기 농축 단계는 복합 천연 추출물에 당 조성물을 1 : 30 ~ 1 중량비로 혼합할 수 있다.Preferably, the concentration step may be carried out by mixing the sugar composition with the complex natural extract at a weight ratio of 1: 30 to 1: 1.
상기 유산균은, 락토바실러스 애시도필루스, 락토바실러스 카세이, 락토바실러스 플란타룸, 락토바실러스 람노서스, 락토바실러스 퍼멘텀, 락토바실러스 불가리쿠스, 락토바실러스 델브루에키아종 락티스, 락토바실러스 가세리 비피도박테리움 브레베 및 락토바실러스 서머필러스로 이루어진 군 중에서 선택된 1종 이상을 포함하는 것이 바람직하다.The lactic acid bacteria may be selected from the group consisting of Lactobacillus ashidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus lambosus, Lactobacillus perfumant, Lactobacillus bulgaricus, Lactobacillus delbrueckiacha lactis, Lactobacillus gasseri Bifidobacterium breve, and Lactobacillus thermophilus. [0031] The term " bifidobacterium "
또한, 상기 발효단계는, 복합 천연 농축액에 유산균을 접종하되, 상기 유산균의 초기 균 수는 107 ~ 109 CFU/ml 인 것을 사용할 수 있다.Also, in the fermentation step, the complex natural concentrate is inoculated with lactic acid bacteria, and the initial number of bacteria of the lactic acid bacteria is 107 to 109 CFU / ml.
한편, 본 발명의 다른 실시 형태는 앞서 언급한 제조방법으로 제조된 장내 환경 개선 및 면역 증강용 조성물이다.Meanwhile, another embodiment of the present invention is a composition for intestinal environment improvement and immunity enhancement produced by the aforementioned production method.
본 발명은, 인체의 장 내부의 건강 기능성을 향상시킬 수 있는 유효 성분이 함유된 천연식물을 추출, 발효하여 조성물을 제조함으로써, 장내 서식하는 유산균과 같이 건강에 유익한 균은 활성화 시키고, 장내 부패균을 억제하여 장내 환경을 개선할 수 있다.The present invention relates to a method for activating healthy bacteria such as lactic acid bacteria in the intestines by extracting and fermenting natural plants containing effective ingredients capable of improving health function in the intestines of the human body to activate them, The intestinal environment can be improved.
이하 본 발명의 바람직한 실시 예를 통해 상세히 설명하기에 앞서, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정하여 해석되어서는 아니 되며, 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야 함을 밝혀둔다.DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings. Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. As well as the fact that
본 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있는 것을 의미한다.Throughout this specification, when an element is referred to as " including " an element, it is understood that it may include other elements as well, without departing from the other elements unless specifically stated otherwise.
또한, 본 명세서 내에서 특정 물질의 농도를 나타내기 위하여 사용되는 “%”는 별도의 언급이 없는 경우, 고체/고체는 (중량/중량)%, 고체/액체는 (중량/부피)% 그리고 액체/액체는 (부피/부피)%이다.The term "% " used herein to denote the concentration of a specific substance in the present specification includes solid / solid (weight / weight), solid / liquid (weight / volume) / Liquid is (volume / volume)%.
이하에서는 본 발명의 장내 환경 개선 및 면역기능 증강용 조성물의 제조방법 및 이에 의해 제조된 장내 환경 개선 및 면역기능 증강용 조성물에 관하여 보다 상세히 설명하고자 한다.Hereinafter, the intestinal environment improvement and the method for preparing the composition for enhancing the immune function and the composition for enhancing the intestinal environment and enhancing the immune function produced by the method will be described in detail.
먼저, 본 발명은 장 기능을 활성화시킬 수 있는 유효 성분이 포함된 천연 식물을 추출하여 수득된 추출물에 유산균을 접종하여 발효시켜 제조하여, 장내 서식하는 유산균과 같이 건강에 유익한 균은 활성화 시키고, 장내 부패균을 억제하여 장내 환경을 개선하고, 면역기능을 활성화시킬 수 있는 조성물을 제공할 수 있다. First, the present invention relates to a method for activating a bacterium which is beneficial to health, such as lactic acid bacteria in the intestines, by fermenting lactic acid bacteria inoculated with the extract obtained by extracting a natural plant containing an active ingredient capable of activating the intestinal function, It is possible to provide a composition capable of suppressing spoilage bacteria to improve intestinal environment and activate immune function.
바람직하게는 연근, 블루베리, 생강 및 곡물 중 하나 이상을 분쇄하여 분쇄물을 제조하는 분쇄 단계; 상기 분쇄물을 중탕기를 사용하여 유효 성분을 추출하여 복합 천연 추출물을 제조하는 추출 단계; 상기 복합 천연 추출물을 가열하여 농축하는 농축 단계; 상기 농축 단계를 통해 수득된 복합 천연 농축액에 유산균을 접종하여 발효시키는 발효 단계; 및 상기 발효단계를 통해 수득된 복합 천연 발효물의 이물질을 제거하는 여과 단계;를 포함하여 장내 환경 개선 및 면역기능 증강용 조성물을 제조할 수 있다.A pulverizing step of pulverizing at least one of Lotus root, Blueberry, Ginger and Grain to produce a pulverized product; An extracting step of extracting the pulverized material from the active ingredient using a stewer to prepare a complex natural extract; Concentrating the complex natural extract by heating; A fermentation step of inoculating lactic acid bacteria into the complex natural concentrate obtained through the concentration step to ferment; And a filtration step of removing impurities of the complex natural fermentation product obtained through the fermentation step, thereby preparing a composition for enhancing the intestinal environment and enhancing the immune function.
본 발명의 장내 환경 개선 및 면역기능 증강용 조성물을 제조하기 위해 사용되는 천연물은 일반적으로 장기능 개선 효과가 있다고 알려진 천연 식물, 약용 식물, 한약재이면 한정되지 않고 사용가능하나, 바람직하게는 연근, 블루베리, 생강 및 곡물 중 적어도 하나 이상일 수 있으며, 더욱 바람직하게는 연근, 블루베리, 생강 및 곡물을 혼합한 것을 사용할 수 있다. 한편, 상기 곡물은 일반적으로 곡류로 구분되는 것이면 모두 다 사용가능하며, 바람직하게는 콩, 귀리, 미강, 현미 또는 호분층 일 수 있다.The natural product used for preparing the composition for enhancing the intestinal environment and enhancing the immune function of the present invention is not particularly limited as long as it is a natural plant, a medicinal plant, or a medicinal herb that is generally known to have an intestinal function improving effect. Berries, ginger, and grains, and more preferably, a mixture of lotus root, blueberry, ginger, and grains can be used. On the other hand, the grain can be generally used as long as it is generally classified into cereals, and preferably beans, oats, rice gruel, brown rice or a horny layer.
상기 연근은, 연근(Nelumbo nucifera Gaern)은 연의 뿌리를 말하는 것으로써, 주성분은 탄수화물로 식물성 섬유가 풍부하게 들어 있으며, 이 식물성섬유는 장벽을 더 자극하여 장내의 활동을 활발하게 해주며 아스파라긴 약 2%를 비롯하여 알기닌, 티로신, 트리코네린 등의 아미노산을 함유하고 있으며, 인지질인 레시틴이 풍부한 것으로 알려져 있다. 특히, 연근에는 실과 같은 끈끈한 뮤신이라는 당단백질 물질이 있어 당질과 결합된 복합 단백질로 콜리스테롤 저하 작용과 위벽보호, 해독작용에 탁월한 효과가 있는 것으로 알려져 있다.The root of the lotus root (Nelumbo nucifera Gaern) refers to the roots of the Yan, the main component is a carbohydrate rich in vegetable fiber, which stimulates the action of the intestines further stimulates the barrier and asparagine about 2 %, Amino acids such as arginine, tyrosine, and tricholine, and it is known that lecithin, which is a phospholipid, is abundant. In particular, there is a glycoprotein substance called sticky mucin in the lotus root, which is known to have an excellent effect on the action of lowering the cholesterol, protecting the gastric wall, and detoxifying the carbohydrate complex protein.
상기 블루베리는 안토시아닌 성분이 껍질에 많이 함유되어 있는데 안토시아닌은 피를 맑게 해 심장질환과 뇌졸중 위험을 감소시키며 혈관에 침전물이 쌓이는 것을 방지한다. 또한, 블루베리에 함유된 안토시아닌은 혈관뿐 아니라 시력보호에도 탁월한 효과가 있다고 알려져 있으며, 노화방지, 변비예방에 효과가 있다.The blueberries contain a large amount of anthocyanin in the skin. Anthocyanins cleanse blood to reduce the risk of heart disease and stroke, and to prevent deposits from accumulating in blood vessels. In addition, anthocyanins contained in blueberries are known to exert excellent effects not only on blood vessels but also on sight protection, and are effective in preventing aging and constipation.
상기 생강(Zingiber officinale)은 뿌리줄기는 옆으로 자라고 다육질이며 덩어리 모양이고 황색이며 매운맛과 향긋한 냄새가 있다. 고려시대 이전부터 재배했으리라 추정되고, 고려시대 문헌인 《향약구급방》에는 약용 식물로 기록돼 있다. 뿌리줄기는 말려 갈아서 빵, 과자, 카레, 소스, 피클 등에 향신료로 사용하고, 껍질을 벗기고 끓인 후 시럽에 넣어 절이기도 하며 생강차와 생강주 등을 만들기도 한다. 한방에서는 뿌리줄기 말린 것을 건강(乾薑)이라는 약재로 쓰는데, 소화불량, 구토, 설사에 효과가 있고, 혈액 순환을 촉진하며, 항염증과 진통 효과가 있다고 알려져 있다. 특히, 생강에 들어 있는 디아스타아제와 단백질 분해효소가 소화액의 분비를 자극하고 장운동을 촉진시키며 구역질과 설사를 치료하는 작용을 하며, 생강의 맵싸한 성분인 진저롤과 쇼가올은 각종 병원성균, 특히 티푸스균이나 콜레라균 등에 대해 강한 살균작용이 있다.The root of the ginger (Zingiber officinale) grows sideways and is fleshy, lumpy, yellow, with a pungent and fragrant smell. It is presumed that it had been cultivated before the Goryeo Dynasty, and it is recorded as a medicinal plant in the "Kyungpookyangbangbang" which is the literature of Goryeo period. Root stalks are dried and used as spices for bread, cookies, curry, sauces, pickles, etc., peeled, boiled, put into syrup, cut into ginger tea and ginger. In the oriental medicine, dried roots are used as medicines for health (dryness), which is effective for digestion, vomiting and diarrhea, promotes blood circulation, and has anti-inflammatory and analgesic effects. In particular, diastase and proteolytic enzyme in ginger stimulate the secretion of digestive juices, promote bowel movements, and treat nausea and diarrhea. Ginger and shoga, which are gorgeous ingredients of ginger, There is strong bactericidal action against bacteria and cholera.
일반적으로 곡물은 이눌린, 단백질, 칼슘 및 폴리페놀류 등이 풍부하게 함유되어 있어 변비 개선 효과가 우수한 것으로 알려져 있으며, 특히 곡물 중에서도 콩, 귀리, 미강, 현미 또는 호분층에서 선택된 1종 이상을 사용할 수 있다.In general, grains are rich in inulin, protein, calcium, and polyphenols, and are known to have excellent constipation-improving effects. In particular, grains can use one or more selected from soybean, oat, rice gruel, brown rice or chaff.
콩(soybean, Glycinemax)은 대두(大豆)라고도 하며, 흑콩, 백콩, 강낭콩, 피강낭콩 등 여러 종류가 있다. 일반적으로 콩은 지질 20 %, 단백질 40 %, 탄수화물 35 %, 수분 12 ~ 14 % 이루어져 있다. 특히, 콩 내 지방산에는 리놀레산(linoleic acid)이 55%, 올레산(oleic acid)이 22% 정도로 불포화지방산이 풍부할 뿐 아니라 혈관계질환에 매우 효과적인 ω-3 지방산인 리놀렌산(linolenic acid)도 10% 정도 함유하고 있어 매우 우수한 지질 공급원이다. 또한, 콩에는 콜레스테롤(cholesterol)이 전혀 없으며 생체막의 노화방지 효과가 있는 토코페롤(tocopherol)이 다량 함유되어 있고, 식물성 스테롤(sterol)도 존재한다. 이외에도 기억력을 증진시킨다고 알려진 레시틴(lecithin)이 함유되어 있다. 그밖에 사포닌이나 파이토에스트로젠(phytoestrogen)인 이소플라본, 올리고당과 같은 기능성 성분도 널리 알려져 있다.Soybeans (soybean, Glycinemax) are also called soybeans, and there are many kinds such as black beans, white beans, kidney beans, and beans. Generally, soybeans consist of 20% lipid, 40% protein, 35% carbohydrate and 12-14% moisture. Particularly, soybean fatty acid has a linoleic acid content of 55%, an oleic acid content of about 22%, and an omega-3 fatty acid linolenic acid, which is highly effective for vascular diseases, is about 10% And is a very good lipid source. In addition, there is no cholesterol in soybeans, and it contains a large amount of tocopherol, which has antioxidant effect on biological membranes, and there is also plant sterol. In addition, lecithin is known to enhance memory. Functional components such as saponins and phytoestrogens such as isoflavones and oligosaccharides are also widely known.
또한, 상기 콩 내 단백질 주요성분은 글로블린인 글리시닌과 알부민인 레구멜린(legumelin)으로 되어 있으며, 크론병이나 궤양성 대장염을 일컫는 염증성 잘 질환(IBD) 증상을 완화시키는 효과가 있는 것으로 알려져 있다. In addition, the main protein of the soybean is composed of globulin glycinein and albumin legumelin, and is known to have the effect of relieving inflammatory benign disease (IBD) symptom called Crohn's disease or ulcerative colitis .
상기 귀리(oat, Avena sativa L.)는 외떡잎식물 벼목 화본과의 두해살이풀로서 열매를 곱게 빻은 것을 오트밀이라 하여 식용하고 알코올·과자의 원료 또는 가축의 사료로 쓴다. 우리나라 식품의약품안전처의 건강기능식품으로 허가된 원료인 귀리식이섬유(0.8g/1일 이상)는 기능성분(또는 지표성분)의 함량이 식이섬유를 200 mg/g이상 함유하고 있어야 한다. 귀리식이섬유소의 대부분은 수용성 식이섬유로 혈중 콜레스테롤 개선·식후 혈당상승 억제에 도움을 줄 수 있다. 다량의 식이섬유로 혈당 조절기능 외에도 변비개선에 효과가 있다고 알려져 있다.The oat (oven, Avena sativa L.) is a biennial plant of the alcoholi plant Laminaria japonica, which is finely pulverized and is used as oatmeal and used as feed for alcohol, confectionery or livestock. Oat dietary fiber (0.8 g / day or more), a raw material approved as a health functional food by Korea Food and Drug Administration, should contain 200 mg / g or more of dietary fiber content of functional ingredient (or indicator ingredient). Most of oat dietary fiber is water-soluble dietary fiber, which can help improve blood cholesterol and postprandial blood glucose. A large amount of dietary fiber is known to be effective in improving constipation as well as controlling blood sugar.
상기 미강은 벼에서 왕겨를 뽑고 난 다음, 현미를 백미로 도정하는 공정에서 분리되는 고운 속겨를 의미한다. 통상적으로 미강이란 쌀눈과 호분층을 말하는데, 이러한 미강에는 레시친, 옥타코사놀, 오리자놀, 토코페롤 등 생리활성 물질이 약 95%가 분포하고, 나머지 생리활성 물질은 백미라고 하는 쌀에 분포한다고 알려져 있다. 미강은 비타민 A, 비타민 B1, B6, 철분, 인, 미네랄 등 다양한 영양소가 함유되어 있다. 미강은 수분 13.5%, 단백질 13.2%, 지방 18.3%, 당질 38.3%, 섬유 7.8%, 회분 8.9%의 조성 성분으로 이루어져 있다.The rice bran means a fine bruch which is separated from the process of removing rice hulls from rice and then turning brown rice into white rice. It is generally known that rice bran and rice hulls are rice bran, and about 95% of physiologically active substances such as lecithin, octacosanol, orozanol, and tocopherol are distributed in rice bran, and the remaining bioactive substances are distributed in rice called rice bran. Rice cores contain various nutrients such as vitamin A, vitamin B1, B6, iron, phosphorus and minerals. Rice cores consist of 13.5% moisture, 13.2% protein, 18.3% fat, 38.3% carbohydrate, 7.8% fiber and 8.9% ash.
특히, 미강은 비타민 B1은 100g 중 2.5 ㎎만큼 함유되어 있을 뿐만 아니라, 식이섬유가 풍부하여 장의 작용을 활발하게 하여 변비에 탁월한 효과가 있다.In particular, rice bran contains not only 2.5 mg of vitamin B1 in 100 g, but also has excellent effect on constipation because it is enriched with dietary fiber and makes intestinal action active.
또한, 미강은 장내의 버피스균과 같은 유익균을 증가시켜 장 안에 기생하고 있는 세균의 밸런스를 유지시킬 수 있으며, 이로 인해 대장암 예방에 효과가 있다.In addition, rice bran can increase the number of beneficial bacteria such as buppies in the intestines, thereby maintaining the balance of bacteria parasitic in the intestines.
뿐만 아니라, 미강은 소장 내 칼슘의 흡수를 억제하는 작용할 할 수 있다. 이에 따라, 결석을 예방하는 효과가 우수한 것으로 알려져 있다.In addition, rice bran can act to inhibit the absorption of calcium in the small intestine. Thus, it is known that the effect of preventing stones is excellent.
한편, 상기 곡물로 사용될 수 있는 현미(玄米)는 수확한 벼에서 왕겨만 제거한 상태의 쌀을 의미한다. 현미는 겨층(과피, 종피, 호분층), 배아(쌀눈), 및 배유(배젖)로 구성되어 있으며 영양분은 배아(쌀눈)에 66%, 겨층 및 내피에 29%, 배유에 5% 정도로 분포되어 있다.On the other hand, brown rice, which can be used as the grain, refers to rice in which only rice hulls have been removed from the harvested rice. Brown rice consists of crustacean (pea, seed coat, hornblende), embryo (rice husk), and endosperm (endosperm). Nutrients are distributed in 66% of embryo (rice), 29% in chaff and endothelia and 5% .
상기 호분층(糊粉層)은 호분립(단백립)을 다량 함유한 세포층으로 벼의 종피(종자의 주위를 덮는 피막의 총칭) 안쪽에 위치한 것을 의미한다. 호분층은 양분 저장 외에 아밀라아제와 기타의 효소를 분비하여 배아 내의 저장 물질을 가용성 성분으로 하여 배아(胚)에 공급하는 작용을 한다. 이런 호분층과 배아에는 알파글리칸, 감마오리자놀, 감마아미노뷰티르산, 피트산, 베타시스테롤, 옥타코사놀, 리놀레산, 식이섬유, 비타민B1, 비타민B2, 비타민E 등이 함유되어 있으며, 이중 알파글리칸과 피트산과 베타시스테롤은 항암작용을 하고, 감마오리자놀과 감마아미노뷰티르산은 뇌세포대사촉진 및 기억력감퇴방지 작용을 하고, 리놀레산은 아토피 피부염 개선작용을 하고, 식이섬유는 변비를 예방하고, 비타민 B1, B2, B6, E와 각종 아미노산은 인체의 대사를 도울 수 있다.The phakic layer is a cell layer containing a large amount of protein lip, which means that it is located inside the seed coat of rice (general name of the coating covering the seeds). In addition to storing nutrients, the phakic layer secretes amylase and other enzymes, and functions to supply the embryo with the storage material in the embryo as a soluble component. These hornbills and embryos contain alpha glycans, gamma oruzanol, gamma amino butyric acid, pitic acid, betacyesterol, octacosanol, linoleic acid, dietary fiber, vitamin B1, vitamin B2 and vitamin E, Gamma oryzanol and gamma aminobutyric acid act to inhibit brain cell metabolism and memory deterioration. Linoleic acid acts to improve atopic dermatitis, dietary fiber prevents constipation, and vitamin B1 , B2, B6, E and various amino acids can help the metabolism of the human body.
본 발명의 분쇄단계는, 앞서 언급한 바와 같이 장기능 개선, 장내 유익균의 활성화를 통해 장내 환경을 개선시켜 줄 수 있는 유효 성분이 포함된 천연물인 연근, 블루베리, 생강 및 곡물을 혼합한 다음, 소정의 입도로 분쇄하는 것이 바람직하다. 이는 후속공정의 추출 단계에서 천연물 내 포함된 유효 성분의 추출 효율을 향상시킴과 동시에 상기 연근, 블루베리, 생강 및 곡물 중 적어도 둘 이상을 선택할 경우 각각의 재료 내 포함된 유효 성분들이 충분히 용출될 수 있도록 하기 위함이다.The crushing step of the present invention may be carried out by mixing rootstocks, blueberries, ginger, and grains, which are natural products containing active ingredients capable of improving the intestinal environment through improvement of intestinal function and activation of intestinal beneficial bacteria, It is preferable to crush to a predetermined particle size. This improves the extraction efficiency of the active ingredient contained in the natural product in the extraction step of the subsequent process, and when at least two of the lotus root, blueberry, ginger and grain are selected, the active ingredients contained in each material can be sufficiently eluted .
바람직하게는 상기 분쇄단계는, 연근, 블루베리, 생강 및 곡물을 1 : 0.1 ~ 10 : 0.1~ 10 : 0.1 ~ 10 중량비율로 혼합한 혼합물을 분쇄할 수 있다. 이는 반복적인 실험을 통하여 건강에 유익한 균은 활성화 시키고, 장내 부패균을 억제하여 장내 환경을 개선하고, 면역기능을 활성화시킬 수 있을 뿐만 아니라, 연근 및 생각 특유의 이취와 쓴 맛, 떫은 맛을 중화시켜 소비자의 기호도를 향상시킬 수 있는 최적의 비율을 도출한 것이다.Preferably, the pulverization step may be carried out by pulverizing a mixture of a lotus root, blueberry, ginger and grain in a ratio of 1: 0.1 to 10: 0.1 to 10: 0.1 to 10 by weight. Through repeated experiments, it is possible to activate healthy bacterium for health, to suppress intestinal decongestant bacteria, to improve the intestinal environment, to activate immune function, to neutralize the odor, bitter taste, And the optimal ratio that can improve the preference of consumers is derived.
바람직하게는 상기 분쇄단계에서 연근, 블루베리, 생강 및 곡물을 포함하는 혼합물은 150 ~ 700 Mesh 크기로 분쇄할 수 있으며, 분쇄된 혼합물의 입도가 150 Mesh 미만일 경우 미세한 분쇄로 인한 추출 효율 증가 효과가 없어 경제성이 저하될 뿐만 아니라, 미분으로 인하여 제조공정 중 분진이 발생될 수 있다. 또한, 분쇄된 혼합물의 입도가 700 Mesh를 초과할 경우 각각의 재료 내 포함된 유효 성분이 충분이 용출되지 않아 건강에 유익한 균은 활성화 시키고, 장내 부패균을 억제하여 장내 환경을 개선하고, 면역기능을 활성화시키는 효과를 기대하기 어렵다.Preferably, in the pulverizing step, the mixture including the rootstocks, blueberries, ginger and grains can be ground to a size of 150 to 700 Mesh, and when the particle size of the ground mixture is less than 150 Mesh, the effect of increasing the extraction efficiency due to fine grinding Not only the economical efficiency is lowered but also dust may be generated during the manufacturing process due to the fine powder. In addition, when the particle size of the ground mixture exceeds 700 Mesh, the active ingredients contained in each material are not sufficiently eluted, thereby activating health-friendly bacteria, inhibiting intestinal decongestants to improve the intestinal environment, It is difficult to expect the effect of activation.
상기 분쇄단계를 통해 분쇄된 분쇄물은 중탕기를 사용하여 천연물 내 함유된 유효 성분을 추출하여 복합 천연 추출물을 제조하는 추출단계를 거칠 수 있다.The pulverized material pulverized through the pulverization step may be subjected to an extraction step of extracting the active ingredient contained in the natural material using a stew pot to prepare a complex natural extract.
바람직하게는 상기 분쇄물을 중탕기를 사용하여 40 ~ 80 ℃ 온도로, 300 ~ 500 bar의 압력을 가하여 복합 천연 추출물을 제조할 수 있다. 상기 추출 단계의 추출 온도 및 압력은 수득된 복합 천연 추출물 내 연근, 블루베리, 생강 및 곡물의 유효 성분이 장내 환경 개선 및 면역력 향상의 유의적인 효과를 기대할 수 있도록 충분히 추출될 수 있는 바람직한 조건을 한정한 것이다. 따라서 추출 단계의 추출 온도 및 압력이 앞서 제시된 바람직한 범위를 벗어나게 되는 경우 추출된 유효성분이 고온 또는 고압으로 인하여 변성될 수 있거나 충분히 추출되지 않아 유의적인 효과를 기대할 수 없다.Preferably, the pulverized material is pressurized at a temperature of 40 to 80 DEG C and a pressure of 300 to 500 bar using a boiler to produce a complex natural extract. The extraction temperature and pressure in the extraction step may be determined by limiting the effective conditions of the active ingredient of the lotus root, blueberry, ginger, and grains in the obtained complex natural extract to be sufficiently extracted so as to expect a significant effect of improving the intestinal environment and improving immunity It is. Therefore, when the extraction temperature and pressure in the extraction step are outside the preferable range, the extracted active ingredient may be denatured due to high temperature or high pressure or can not be sufficiently extracted, so that a significant effect can not be expected.
상기 추출 단계에서 추출된 복합 천연 추출물을 가열하여 수분의 함량을 줄여 농축하는 것이 바람직하며, 이 때 상기 복합 천연 추출물에 당 조성물을 더 포함할 수 있다. 이 때, 상기 당 조성물은 포도당, 과당, 갈락토오스, 자당, 맥아당, 젖당 중에서 선택된 하나 이상을 사용하는 것이 바람직하다.It is preferable to heat the complex natural extract extracted in the extraction step to reduce the moisture content, and the composition may further contain the sugar composition in the complex natural extract. At this time, it is preferable to use at least one selected from glucose, fructose, galactose, sucrose, maltose and lactose.
구체적으로 상기 농축단계는, 복합 천연 추출물에 당 조성물을 1 : 30 ~ 1 중량비로 혼합한 다음 가열하여 상기 복합 천연 추출물 내 수분 함량을 저감시켜 복합 천연 농축액을 제조할 수 있다.Specifically, the concentration step may comprise mixing the sugar composition with the complex natural extract at a weight ratio of 1: 30 to 1, followed by heating to reduce the water content in the complex natural extract, thereby preparing a complex natural concentrate.
상기 복합 천연 추출물과 당 조성물을 혼합 비율은 반복적인 실험을 통하여 제조된 본 발명의 장내 환경 개선 및 면역기증 증강용 조성물에 단맛을 부여하고 천연물 특유의 쓴맛을 중화시켜 소비자의 기호성을 향상시킬 수 있을 수 있는 바람직한 비율을 한정한 것이다. 또한, 본 발명의 조성물 내 당 조성물을 더 포함함으로써, 후속 공정으로 유산균을 접종하여 발효 시 유산균이 상기 당 조성물을 에너지원으로 이용하여 유산을 생성함으로써 원활하게 배양 및 증식되도록 도움을 줄 수 있다.The mixing ratio of the complex natural extract to the sugar composition can be improved by adding sweetness to the composition for enhancing intestinal environment and enhancing immunity of the present invention produced through repeated experiments and neutralizing the bitter taste peculiar to the natural substance Lt; / RTI > In addition, by further containing the sugar composition in the composition of the present invention, lactic acid bacteria can be inoculated in a subsequent step, and lactic acid bacteria can be cultured and propagated smoothly by producing lactic acid bacteria using the sugar composition as an energy source during fermentation.
상기 농축 단계에서 수득된 복합 천연 농축액에 유산균을 접종하여 발효시키는 발효 단계를 수행하여 복합 천연 발효물을 제조할 수 있으며, 상기 복합 천연 발효물의 이물질을 제거하는 여과 단계를 통해 본 발명의 장내 환경 개선 및 면역기능 증강용 조성물을 제조할 수 있다.The complex natural fermented product can be prepared by performing a fermentation step of fermenting the complex natural concentrate obtained in the concentration step by inoculating the lactic acid bacteria and fermenting the complex natural concentrate. The filtration step of removing the foreign substances of the complex natural fermented product, And a composition for enhancing immune function can be prepared.
상기 발효 단계에서 사용되는 유산균, 락토바실러스 애시도필루스, 락토바실러스 카세이, 락토바실러스 플란타룸, 락토바실러스 람노서스, 락토바실러스 퍼멘텀, 락토바실러스 불가리쿠스, 락토바실러스 델브루에키아종 락티스, 락토바실러스 가세리 비피도박테리움 브레베 및 락토바실러스 서머필러스로 이루어진 군 중에서 선택된 1종 이상을 포함할 수 있다.Lactobacillus acidophilus, lactobacillus casei, lactobacillus plantarum, lactobacillus lambosus, lactobacillus fermentum, lactobacillus bulgaricus, lactobacillus delbruecki lactus, lactobacillus strain, Lactobacillus acidophilus, Lactobacillus gasseri bifidobacterium breve, and Lactobacillus thermophilus.
바람직하게는 장내환경개선을 통한 면역력을 높이기 위하여 유산균으로 락토바실러스 애시도필루스, 락토바실러스 플란타룸, 락토바실러스 람노서스 중 하나 이상을 사용할 수 있다.Preferably, one or more of lactobacillus acidophilus, lactobacillus plantarum, and lactobacillus lambosus may be used as the lactic acid bacteria in order to enhance the immunity by improving intestinal environment.
상기 락토바실러스 애시도필루스(Lactobacillus acidophilus)는 종양 억제 효과가 있으며, 당뇨병 환자의 혈중 콜레스테롤 농도를 개선시켜준다. 또한 항염증, 항산화 효과도 가지고 있다. 또한, 상기 락토바실러스 플란타룸(Lactobacillus plantarum)은 소화불량, 소화기능 저하를 감소시켜주고, 각종 치료물질과 단백질을 체내에 전달하는 기능을 가진다. 또한, 유해균을 파괴하고 영양원, 항산화물질 등을 보호해주는 특성이 있다. 그리고 상기 락토바실러스 람노서스(Lactobacillus rhamnosus)는 내산성이 강하여 장내 정착력이 높아 장내 독성물질을 감소시키고, 유해균의 침입을 억제함으로써 아토피, 알레르기등의 면역질환 개선에 도움을 줄 수 있다.The Lactobacillus acidophilus has a tumor suppressive effect and improves blood cholesterol concentration in diabetic patients. It also has anti-inflammatory and antioxidant effects. In addition, the Lactobacillus plantarum has a function of reducing indigestion and degradation of digestive function, and transferring various therapeutic substances and proteins into the body. In addition, there is a characteristic that it destroys harmful bacteria and protects nutrients and antioxidants. The Lactobacillus rhamnosus is highly resistant to acid, so it has a high intestinal fixation ability, thereby reducing intestinal toxic substances and inhibiting the invasion of harmful bacteria, thereby helping to improve immune diseases such as atopy and allergy.
바람직하게는 상기 발효 단계는, 복합 천연 농축액에 유산균을 접종하되, 이 때 유산균의 초기 균 수는 107 ~ 109 CFU/ml 일 수 있다.Preferably, in the fermentation step, the complex natural concentrate is inoculated with lactic acid bacteria, wherein the initial number of lactic acid bacteria is 107 to 109 CFU / ml.
상기 발효 단계를 통해 발효된 복합 천연 발효물은 제조과정 또는 발효과정 중 인입되는 이물질 또는 발효과정에서 생성되는 기포, 거품 등과 같이 시각적으로 저해되거나 제조된 조성물의 향미와 풍미를 저감시키는 것을 제거하기 위하여 여과단계를 거치는 것이 바람직하다.The composite natural fermented product fermented through the fermentation step is used to remove visually impaired or reduced flavor and flavor of the composition such as air bubbles or foam produced during the fermentation process or fermentation process It is preferable to pass through the filtration step.
상기 여과 단계는 한 번의 필터 공정으로 수행될 수도 있고, 2회 이상 다단의 필터 공정으로 수행될 수도 있다.The filtration step may be performed in a single filter process or may be performed in a multi-stage filter process more than two times.
한편, 본 발명의 다른 실시 형태는, 앞서 언급한 제조방법으로 제조된 장내 환경 개선 및 면역기능 증강용 조성물로서, 상기 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁액, 에멀젼, 시럽제, 에어로졸, 외용제, 좌제 및 주사제로 이루어진 군으로부터 선택되는 형태로 제조될 수 있다.Meanwhile, another embodiment of the present invention is a composition for enhancing intestinal environment and enhancing immune function produced by the aforementioned production method, wherein the composition is in the form of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols , External preparations, suppositories, and injections.
또한, 본 발명의 장내 환경 개선 및 면역기능 증강용 조성물이 유효한 약리 효과가 발현될 수 있도록 적절한 양을 포함하여 건강 기능 식품을 제조될 수 있으며, 이 때 상기 건강 기능 식품은 분말, 과립, 정제, 캡슐, 캔디, 츄잉껌, 젤리 및 음료로 이루어진 군으로부터 선택되는 제형일 수 있다.In addition, the health functional food may be prepared in an appropriate amount so that the intestinal environment improving and immune function enhancing composition of the present invention can exhibit effective pharmacological effect, wherein the health functional food is powder, granule, Capsules, candies, chewing gums, jellies, and beverages.
이하에서는, 본 발명의 실시 예를 살펴본다. 그러나 본 발명의 범주가 이하의 바람직한 실시 예에 한정되는 것은 아니며, 당업자라면 본 발명의 권리범위 내에서 본 명세서에 기재된 내용의 여러 가지 변형된 형태를 실시할 수 있다.Hereinafter, an embodiment of the present invention will be described. However, the scope of the present invention is not limited to the following preferred embodiments. Those skilled in the art can implement various modified embodiments of the present invention within the scope of the present invention.
[제조예][Manufacturing Example]
연근, 블루베리, 생강, 곡물을 하기 표 1과 같은 비율로 혼합한 다음, 이를 분쇄하여 분쇄물을 제조하였다. 제조된 분쇄물은 중탕기를 사용하여 70 ℃ 온도에서, 400 bar의 압력을 가하여 복합 천연 추출물을 제조하였다. 제조된 복합 천연 추출액 30 g에 포도당 800 g을 혼합한 다음, 약불로 가열하여 수분이 증발된 복합 천연 농축액을 제조하였다. 상기 복합 천연 농축액에 배양된 유산균으로 락토바실러스 애시도필루스 108 CFU/ml 을 접종한 다음 방치하여 발효시킨 후 여과지를 사용하여 3회 반복하여 여과시켜 실시예 1 및 비교예 1 내지 3의 장내 환경 개선 및 면역기능 증강용 조성물을 제조하였다.Lotus root, blueberry, ginger, and grains were mixed in the ratios shown in Table 1, and then pulverized to prepare pulverized products. The resulting pulverized product was pressurized at a pressure of 400 bar at a temperature of 70 캜 using a steamer to prepare a composite natural extract. 30 g of the complexed natural extract was mixed with 800 g of glucose and heated to about 80 ° C to prepare a complex natural concentrate. Lactobacillus ashidophyllus 108 CFU / ml was inoculated with the lactic acid bacteria cultured in the complex natural concentrate, followed by fermentation after being inoculated and allowed to pass through the filter paper three times repeatedly to obtain intestinal environment of Example 1 and Comparative Examples 1 to 3 And a composition for enhancing immune function were prepared.
(콩:미강:귀리=1:1:1, 중량비)grain
(Beans: rice bran: oats = 1: 1: 1, weight ratio)
(단위 : g)(Unit: g)
[실험예][Experimental Example]
1. 장내 유해균에 대한 성장억제활성 측정.1. Measurement of growth inhibitory activity against enteric bacteria in intestines.
장내 유익균으로 롱검(B. longum ATCC 15707)과 락토바실러스 카제이(Lactobacillus casei ATCC 27216)을 실험실에서 배양하여 사용하였고, 장내 유해균으로는 가스 괴저균(Clostridium perfringens ATCC 13124) 및 대장균(Escherichia coli ATCC 11775)를 배양하여 사용하였다. B. longum ATCC 15707 and Lactobacillus casei ATCC 27216 were cultured in the laboratory and used as enteric bacteria in the intestinal flora including Clostridium perfringens ATCC 13124 and Escherichia coli ATCC 11775 ) Were cultured and used.
이때, 상기 균들의 농도를 20 mg/disc로 노출시킨 결과, 배지 상 관찰영역 지름(zone diameter)이 >30 mm이면 강력한(++++) 성장억제활성, 30-20 mm이면 강한(+++) 성장억제활성, 16-20 mm이면 중간(++) 성장억제활성, 10-15 mm이면 약한(+) 성장억제활성, 및 <10 mm이면 무응답 "-"으로 표기하였다.As a result of exposing the concentration of the microorganisms to 20 mg / disc, when the zone diameter of the medium was> 30 mm, strong (++++) growth inhibitory activity was obtained. +) Growth inhibitory activity, middle (++) growth inhibitory activity at 16-20 mm, weak growth inhibitory activity at 10-15 mm, and no response at <10 mm.
카제이Lactobacillus
Kajay
상기 표 2의 결과를 살펴보면, 실시예 1 및 비교예 1, 3의 경우 장내 유익균인 롱검과 락토바실러스 카제이에 대해서는 성장억제활성이 보이지 않았다. As shown in the results of Table 2, the growth inhibitory activity of Example 1 and Comparative Examples 1 and 3 was not observed in the intestinal beneficial bacteria Longham and Lactobacillus casei.
그러나, 비교예 2의 경우에는 장내 유익균인 락토바실러스 카제이에 대해서 약한 성장억제활성을 보인 반면에 장내 유해균인 가스 괴저균과 대장균은 전혀 성장억제활성이 보이지 않았다.However, in the case of Comparative Example 2, the growth inhibitory activity against Lactobacillus casei, which is a beneficial bacteria in the intestines, was shown, whereas the growth inhibitory activity of gas guttatic bacteria and Escherichia coli, which were harmful intestinal bacteria, was not observed at all.
또한, 비교예 1은 장내 유해균인 가스 괴저균에 대한 성장억제활성을 확인할 수 없었다.In addition, the growth inhibitory activity against gas gangrene, which is a harmful bacteria in the intestines, could not be confirmed in Comparative Example 1.
반면에, 유산균을 포함하지 않고 제조된 비교예 2의 경우에는 장내 유해균을 중간, 약한 정도의 성장억제활성을 확인할 수 있었다.On the other hand, in the case of Comparative Example 2 prepared without containing the lactic acid bacterium, it was possible to confirm a medium or weak growth inhibitory activity in the intestinal pathogenic bacteria.
2. 장내 유익균에 대한 생육촉진활성 측정.2. Measurement of growth promoting activity against enteric bacterium in the intestines.
상기 제조에서 제조된 실시예 1, 비교예 1 내지 3의 장내 유익균에 대한 생육촉진활성을 측정하였다. Growth promoting activities of the intestinal beneficial bacteria of Example 1 and Comparative Examples 1 to 3 prepared in the above-mentioned production were measured.
상기 표 3의 결과를 살펴보면, 실시예 1의 경우 장내 유익균인 롱검 및 락토바실러스 카제이에 대해서 성장촉진활성이 비교예 1 내지 3에 비하여 유의적으로 우수한 특징을 갖는 것을 확인할 수 있었다. As shown in Table 3, it was confirmed that the growth promoting activity of Lung gum and Lactobacillus casei in the intestinal beneficial bacteria of Example 1 was significantly superior to that of Comparative Examples 1 to 3.
따라서, 상기 실험예에서와 같이 본 발명의 장내 환경 개선 및 면역기능 증강용 조성물은 내 유익균의 생육촉진활성이 우수한 동시에 장내 유해균에 대한 성장억제활성이 우수하여 장 기능을 개선하는 건강 기능성 향상 효과가 우수함을 확인할 수 있었다.Therefore, as in the above Experimental Example, the composition for enhancing the intestinal environment and enhancing the immune function of the present invention has an excellent growth promoting activity of beneficial bacteria and an excellent growth inhibitory activity against intestinal pathogenic bacteria, And it was confirmed that it is excellent.
Claims (9)
상기 분쇄물을 중탕기를 사용하여 40~80℃의 온도 범위와 300~500bar의 압력범위에서 유효 성분을 추출하여 복합 천연 추출물을 제조하는 추출 단계;
상기 복합 천연 추출물 1 중량부에, 포도당, 과당, 갈락토오스, 자당, 맥아당, 젖당 중 하나 이상을 포함하는 당 조성물을 30~1 중량부로 추가한 후, 가열하여 복합 천연 농축액을 제조하는 농축 단계;
상기 농축 단계를 통해 수득된 복합 천연 농축액에 유산균을 접종하여 발효시키는 발효 단계; 및
상기 발효단계를 통해 수득된 복합 천연 발효물의 이물질을 제거하는 여과 단계;를 포함하고,
상기 곡물은 콩, 귀리, 미강 현미 또는 호분층인 것을 특징으로 하는, 장내 환경 개선용 조성물의 제조방법.
Milling step of grinding a mixture obtained by mixing 1: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10 by weight of lotus root, blueberry, ginger and grain to a size of 150 ~ 700 Mesh;
An extracting step of extracting the active ingredient from the pulverized product in a temperature range of from 40 to 80 ° C and a pressure range of from 300 to 500 bar using a boiler to produce a complex natural extract;
Adding a sugar composition containing at least one of glucose, fructose, galactose, sucrose, maltose and lactose to 1 to 30 parts by weight of the complex natural extract and heating to prepare a complex natural concentrate;
A fermentation step of inoculating lactic acid bacteria into the complex natural concentrate obtained through the concentration step to ferment; And
And a filtration step of removing impurities of the complex natural fermentation product obtained through the fermentation step,
Wherein the cereals are soybeans, oats, rice gruel brown rice or a colony layer.
상기 유산균은, 락토바실러스 애시도필루스, 락토바실러스 카세이, 락토바실러스 플란타룸, 락토바실러스 람노서스, 락토바실러스 퍼멘텀, 락토바실러스 불가리쿠스, 락토바실러스 델브루에키아종 락티스, 락토바실러스 가세리 비피도박테리움 브레베 및 락토바실러스 서머필러스로 이루어진 군 중에서 선택된 1종 이상을 포함하는 것을 특징으로 하는, 장내 환경 개선용 조성물의 제조방법.
The method according to claim 1,
The lactic acid bacteria may be selected from the group consisting of Lactobacillus ashidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus lambosus, Lactobacillus perfumant, Lactobacillus bulgaricus, Lactobacillus delbrueckiacha lactis, Lactobacillus gasseri Wherein the composition comprises at least one selected from the group consisting of Bifidobacterium breve and Lactobacillus thermophilus.
상기 발효단계는, 복합 천연 농축액에 유산균을 접종하되,
상기 유산균의 초기 균 수는 107 ~ 109 CFU/ml 인 것을 특징으로 하는, 장내 환경 개선용 조성물의 제조방법.
The method according to claim 1,
Wherein the fermentation step comprises inoculating the complex natural concentrate with lactic acid bacteria,
Wherein the initial number of bacteria of the lactic acid bacteria is 107 to 109 CFU / ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170122412A KR101945207B1 (en) | 2017-09-22 | 2017-09-22 | Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170122412A KR101945207B1 (en) | 2017-09-22 | 2017-09-22 | Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101945207B1 true KR101945207B1 (en) | 2019-04-17 |
Family
ID=66281559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170122412A KR101945207B1 (en) | 2017-09-22 | 2017-09-22 | Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101945207B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021182895A1 (en) * | 2020-03-11 | 2021-09-16 | 주식회사 엘지생활건강 | Cosmetic composition for increasing beneficial bacteria of skin |
| CN115316479A (en) * | 2022-07-26 | 2022-11-11 | 厦门市养真保健食品有限公司 | Tablet candy containing probiotics and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110118911A (en) * | 2010-04-26 | 2011-11-02 | (주)웰조이 | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof |
| KR101743044B1 (en) | 2016-06-28 | 2017-06-02 | 바이오제닉스코리아 주식회사 | The Functional Health Food For Improving The Intestine Function and Environment and Enhencing Immunity |
-
2017
- 2017-09-22 KR KR1020170122412A patent/KR101945207B1/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110118911A (en) * | 2010-04-26 | 2011-11-02 | (주)웰조이 | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof |
| KR101743044B1 (en) | 2016-06-28 | 2017-06-02 | 바이오제닉스코리아 주식회사 | The Functional Health Food For Improving The Intestine Function and Environment and Enhencing Immunity |
Non-Patent Citations (2)
| Title |
|---|
| "아가변비에 좋은음식 NK세포 프로젝트 N-1 마셔요~", 네이버 블로그(https://blog.naver.com/icic75ji/221051107118) (게재일: 2017.07.14.) * |
| "체온1도의 비밀 청인 생강발효유산균진액", 네이버 블로그(https://blog.naver.com/winplus/220444027774) (게재일: 2015.08.12.) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021182895A1 (en) * | 2020-03-11 | 2021-09-16 | 주식회사 엘지생활건강 | Cosmetic composition for increasing beneficial bacteria of skin |
| CN115209871A (en) * | 2020-03-11 | 2022-10-18 | 株式会社Lg生活健康 | Cosmetic composition for enhancing skin beneficial bacteria |
| CN115316479A (en) * | 2022-07-26 | 2022-11-11 | 厦门市养真保健食品有限公司 | Tablet candy containing probiotics and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104824548B (en) | Matrimony vine compound health ferment and preparation method thereof | |
| CN103027231B (en) | Compound probiotics fermented Chinese herbal medicine active health care liquid and preparation method thereof | |
| KR20130046897A (en) | Composition comprising lactobacillus plantarum dsr ck10 or lactobacillus plantarum dsr m2 as an effective ingredient for treatment of inflammatory diseases | |
| CN105105025B (en) | A kind of powder enzyme food of sprouted unpolished rice preparation | |
| CN107568537A (en) | A kind of compound microorganism ferments beverage containing anthocyanidin and preparation method thereof | |
| KR102379524B1 (en) | Composition for improving, treating or preventing intestinal function or inflammarory bowel disease comprising fermented rice as an active ingredient | |
| KR20160058389A (en) | Method of Manufacturing Volumizing Antocyanine Probiotics Metabolite and Pharmetics, cosmetics and Juice and food complex | |
| KR102257052B1 (en) | Manufacturing method of healthy beverage containing improvement of gastric disease by using the cabbage extracts | |
| CN108936628A (en) | A kind of specific full nutritional formulas and preparation method thereof that patients with cerebral apoplexy is edible | |
| KR102513975B1 (en) | Health functional food composition for improving intestinal health containing psyllium hull | |
| KR101945207B1 (en) | Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method | |
| KR101426501B1 (en) | Fermentational Composition Comprising Portulaca Oleracea L. and Rice Bran and the Method of Manufacturing thereof | |
| KR102139732B1 (en) | Composition for improving immune activity containing lactobacillus | |
| TWI734322B (en) | Kimchi for prevention or treatment of disease related to helicobacter pylori | |
| KR20110118911A (en) | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof | |
| JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
| KR20190072923A (en) | Antioxidant and Immune-enhancing functional beverage and food composition comprising the extract of edible flowers fermented by lactic acid bacteria and preparation method of the same | |
| KR20100037309A (en) | Pill type manufacturing method of health supporting food | |
| KR20100037312A (en) | Powder type manufacturing method of health supporting food | |
| JP2006265142A (en) | Body fat accumulation inhibiting or decreasing agent | |
| Sharma et al. | Fermented fruit and vegetable products as functional foods-An overview | |
| Saibhavani et al. | Chapter-7 role of traditional foods for immunity boosting | |
| KR102337130B1 (en) | Composition comprising fermented Oriental medicine herbs for preventing, improving or treating obesity, and method for preparing the same | |
| KR102633729B1 (en) | Composition for diet to improve constipation and intestinal function | |
| KR102405006B1 (en) | Kombucha composition having diet function |